anti-EGFR recombinant Fc engineered IgA2m antibody (Shire)

N/A

Report date: 2025/03/14 16:38:26

Base Information

Drug Nameanti-EGFR recombinant Fc engineered IgA2m antibody (Shire)
Drug Alias Nameanti-EGFR recombinant Fc engineered IgA2m antibody (Baxalta)
ClassificationBiologics > Protein drugs > Immunoglobulin > AntibodyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSuppremol
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceutical Co Ltd
Inactive CompaniesShireSuppremolBaxalta Incorporated +[4] 
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A